Patents by Inventor Robert Nicholas Willette

Robert Nicholas Willette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9707219
    Abstract: The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 18, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dennis Sprecher, Robert Nicholas Willette
  • Publication number: 20160367542
    Abstract: The use of a nicotinamide derivative in the treatment acute coronary syndrome (ACS) and pharmaceutical compositions used in such treatment.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Michele Ghirardi, David Greenhalgh, Dennis L. Sprecher, Robert Nicholas Willette
  • Publication number: 20160220550
    Abstract: The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 8, 2014
    Publication date: August 4, 2016
    Inventors: Dennis SPRECHER, Robert Nicholas WILLETTE
  • Publication number: 20150209337
    Abstract: The present invention relates to the use of a nicotinamide derivative in the treatment acute coronary syndrome (ACS) and pharmaceutical compositions used in such treatment.
    Type: Application
    Filed: July 9, 2013
    Publication date: July 30, 2015
    Inventors: Michele Ghirardi, David Greenhalgh, Dennis L. Sprecher, Robert Nicholas Willette
  • Publication number: 20100099752
    Abstract: The present invention relates to pharmaceutical compositions containing bicyclic type compounds and to methods of using same, for example, in the treatment or prevention of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse, Parkinson's Disease, psychosis, migraine and/or cerebral ischaemia.
    Type: Application
    Filed: June 17, 2009
    Publication date: April 22, 2010
    Applicant: SmithKline Beecham plc.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Publication number: 20030236410
    Abstract: A compound of formula (I) or pharmaceutically acceptable salt thereof wherein: 1
    Type: Application
    Filed: June 2, 2003
    Publication date: December 25, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Publication number: 20020123630
    Abstract: A compound of formula (I) or pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: September 5, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Publication number: 20010021780
    Abstract: A compound of formula (I) or pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: May 1, 2001
    Publication date: September 13, 2001
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Patent number: 5948811
    Abstract: A compound of formula (I) or pharmaceutically acceptable salt thereof: ##STR1## wherein either Y is N and R.sub.2 is hydrogen, or Y is C--R.sub.1 ; where either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of hydrogen, C.sub.3-8 cycloalkyl, C.sub.1-6 alkyl optionally interrupted by oxygen or substituted by hydroxy, C.sub.1-6 alkoxy or substituted arminocarbonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkoxy, nitro, cyano, halo, trifluoromethyl, CF.sub.3 S, or a group CF.sub.3 --A--, or a group CF.sub.2 H--A'--, trifluoromethoxy, C.sub.1-6 alkylsulphinyl, perfluoro C.sub.2-6 alkylsulphonyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, phosphono, arylcarbonyloxy, heteroarylcarbonyloxy, arylsulphinyl, heteroarylsulphinyl, arylsulphonyl, heteroarylsulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: September 7, 1999
    Assignee: SmithKline Beegham p.l.c.
    Inventors: Wai Ngor Chan, John Morris Evans, Geoffrey Stemp, Neil Upton, Robert Nicholas Willette
  • Patent number: 5908860
    Abstract: This invention relates to the method of treatment and/or prophylaxis of anxiety and/or disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy, using compounds of the formula (Ia): ##STR1##
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: June 1, 1999
    Assignees: SmithKline Beecham plc,, SmithKline Beecham Corporation
    Inventors: Mervyn Thompson, John Morris Evans, Neil Upton, Wai Ngor Chan, Kuok Keong Vong, Robert Nicholas Willette